LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 16
May 09, 2023 16:15 ET
|
LumiraDx Inc
LONDON, May 09, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its first quarter financial results...
LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
April 24, 2023 16:21 ET
|
LumiraDx Inc
LONDON, April 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that...
LumiraDx Announces Strategic Refocus and Cost Restructuring Program
April 06, 2023 09:20 ET
|
LumiraDx Inc
LONDON, April 06, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a leading global provider of point-of-care diagnostics testing solutions, today announced its Strategic Refocus and Cost...
LumiraDx Reports Fourth Quarter and Full Year 2022 Results
March 21, 2023 07:26 ET
|
LumiraDx Inc
LONDON, March 21, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its fourth quarter and...
LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21
March 14, 2023 08:03 ET
|
LumiraDx Inc
LONDON, March 14, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2022...
LumiraDx to Present at Raymond James Institutional Investors Conference
March 03, 2023 09:00 ET
|
LumiraDx Inc
LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that Chief Financial Officer, Dorian LeBlanc, will be presenting at the Raymond James...
LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements
February 17, 2023 16:15 ET
|
LumiraDx Inc
LONDON, Feb. 17, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has...
LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay
February 06, 2023 08:00 ET
|
LumiraDx Inc
LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete assay receives Emergency Use Authorization from the FDA along with being successfully validated by the UK Health Security Agency (UKHSA) under the...
LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK
January 31, 2023 16:30 ET
|
LumiraDx Inc
Run on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is...
LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
January 31, 2023 16:15 ET
|
LumiraDx Inc
LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that...